Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New acne cream shows promise in small safety trial

NCT ID NCT06671834

Symptom relief Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Pfizer completed a Phase 1 study testing a new topical drug called PF-07905428 for acne. The study included 52 healthy volunteers and people with moderate to severe acne, who applied the drug daily for 14 or 28 days. The main goal was to check safety and side effects, not to see if it works. This early research helps decide if larger studies should go forward.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-07905428 (topical solution)
What this could lead to
If it works, this could point toward a new topical treatment for moderate to severe acne.
What could go wrong
This is a very early Phase 1 study with only 52 participants, focused on safety. It is too small to prove effectiveness, and the drug may not work or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

52 people

The number who actually took part.

Started

Nov 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation. * Only for participants who are enrolling with acne vulgaris: diagnosis of acne vulgaris for 3 months or greater * For participants enrolling in Cohort 1-3 with acne vulgaris (optional): mild to moderate facial acne vulgaris * For participants enrolling in Cohort 4 with acne vulgaris: moderate to severe facial acne vulgaris Exclusion Criteria: * Participants with very severe acne * Participants with autoinflammatory syndromes * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease * History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. * Participants with clinically significant laboratory abnormalities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris

Contacts and locations

Locations

  • Innovaderm Research Inc.

    Montreal, Quebec, H2X 2V1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.